Publications Colorectal Cancer
- « overview publications
- Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.
World J Gastroenterol. 2010 Jul 7;16(25):3133-43.
- A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX-6 + Cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients with metastatic colorectal cancer.
T. Ciuleanu, G. Kurteva, J. Ocvirk, S. Beslija, I. Koza, D. Papamichael, D. Vrbanec, T. Brodowicz, W. Scheithauer, C. Zielinski
J. Clin. Oncol (supplement to 26) 2008: #4032
- Comparison of cetuximab plus FOLFOX-6 with cetuximab plus FOLFIRI as first-line therapy in metastatic colorectal cancer: A randomized, open-label phase II CECOG study
T. Ciuleanu, G. Kurteva, J. Ocvirk, S. Beslija, I. Koza, D. Papamichael, D. Vrbanec, T. Brodowicz, W. Scheithauer, C. Zielinski
WCGIC 2008 (#7600)
- A randomized, open-label phase II study evaluating the efficacy and
safety of FOLFOX-6 + cetuximab versus FOLFIRI + cetuximab as first-line
therapy in patients with metastatic colorectal cancer.
T. Ciuleanu, W. Scheithauer, G. Kurteva, J. Ocvirk, I. Koza, D. Papamichael, M. Wenczl, T. Brodowicz, C. Zielinski, S. Beslija.
ECCO, 2007 (#3046).
- Cetuximab plus FOLFOX-6 versus cetuximab plus FOLFIRI as first-line
therapy in patients with metastatic colorectal cancer: A randomized,
open-label phase II CECOG study.
T. Ciuleanu, W. Scheithauer, G. Kurteva, J. Ocvirk, I. Koza, D. Papamichael, M. Wenczl, T. Brodowicz, C. Zielinski, S. Beslija.
ASCO GI 2008, (#339).
For publications of the results of the Consensus Conferenences
see Consensus Statements